DGAP-News

MOLOGEN AG submitted clinical study with MGN1703 in small cell lung cancer - Seite 2

ensures that studies are carried out in accordance with most modern
insights.

About small cell lung cancer
Lung cancer is one of the most common cancer diseases. The two main types
are small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
SCLC is a fast-growing type of lung cancer that usually spreads more
quickly than NSCLC.
In the US the estimated number of new lung cancer cases per year is 228,000
and in Europe it is 410,000. The estimated number of deaths per year is
159,000 in the US and 353,000 in Europe. The proportion of small cell lung
cancer is approximately 15-20% of all lung cancer cases. When first
diagnosed approx. 60-80% of the SCLC-patients have already distant
metastases or extensive local involvement. This advanced stage is called
'extensive disease'. The five-year survival rate for such patients is below
1%.

About MGN1703
MGN1703 is based on dSLIM(R) ('double Stem Loop Immunomodulator'), an
innovative DNA-based TLR9 agonist developed by MOLOGEN. dSLIM(R) activates
the immune system against tumor-associated antigens by targeting various
receptors on certain immune cells, primarily TLR9. Tumor-associated
antigens (TAA) are released by cancer cells as a result of chemotherapy and
radiation therapy. Once activated by dSLIM(R), the immune system is able to
overcome its fatal tolerance toward cancer cells and TAA and attacks them
selectively. Due to this mechanism of action, MGN1703 can be applied to
different indications of cancer.

About MOLOGEN AG
MOLOGEN AG is a publicly listed biotechnology company headquartered in
Berlin and specializes in the research and clinical development of
innovative drugs in the fields of oncology and infectious diseases. One of
the company's most important product candidates is the DNA immunomodulator
MGN1703, which is being clinically developed for colorectal cancer and lung
cancer. The cell-based cancer therapy MGN1601 for the treatment of renal
cancer is also currently at the stage of clinical development. With unique,
patented technologies and innovative product developments, MOLOGEN is one
of the leading biotechnology companies in the fields of DNA medicine and
cell-based therapies.

MOLOGEN AG shares (ISIN DE0006637200) are listed in the Prime Standard of
the German Stock Exchange.

www.mologen.com

Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO Deutschland e.V.
| DECHEMA - Society for chemical technology and biotechnology e.V. |
German industrial association of biotechnology (DIB) | Association for